The latest news from Limbus AI.
Limbus AI Receives ANVISA Marketing Authorization for Limbus Contour™ in Brazil
REGINA, Saskatchewan, Canada August 23, 2023 - Limbus AI Inc. is pleased to announce that it has received full Marketing Authorization (MA) from ANVISA (Agência Nacional de Vigilância Sanitária), the National Health Surveillance Agency of Brazil, for its AI auto-contouring software, Limbus Contour™.
The ANVISA MA is a significant milestone in Limbus AI's ongoing effort to provide efficient treatment planning options to Radiation Therapy professionals. Demonstrating compliance with ANVISA's requirements exemplifies the company's dedication to quality and safety in the field of cancer care.
"The success of Limbus Contour™ in other markets has demonstrated its value in enhancing patient care. Receiving ANVISA's MA allows us to extend our reach into the Brazilian healthcare system," explains Dave Talton, VP of Sales and Marketing at Limbus AI. "We are committed to supporting cancer clinics in Brazil and continue to build on our achievements."
Dr. Karl Otto, CEO at Limbus AI, states, "Limbus Contour™ has earned a reputation for delivering expert-level performance in AI automatic contouring, performed entirely on existing clinical workstations and without the need for cloud transfer of patient data. By significantly reducing contouring time, clinicians can dedicate more time to complex planning tasks and direct patient care. Simple, effective, and compatible with any treatment planning system, Limbus Contour™ has reduced planning times for hundreds of thousands of radiation therapy patients around the world. It represents a standard in quality and reliability, meeting the growing demand for efficiency and precision in radiation treatment planning."
Partnership with Medintec Latin America
Limbus AI Inc. will partner with Medintec Latin America, an established distributor and manufacturer with over 20 years of experience in providing radiation oncology equipment and services in Brazil. Medintec Latin America's dedication to providing the most innovative technology aligns with Limbus AI's mission to provide high quality, reliable and clinically proven solutions. This collaboration leverages Medintec's established presence in Brazil's largest cancer centers, enabling Limbus AI to effectively reach and support the region's oncology community.
“Medintec is proud to partner with Limbus AI to deliver the best in AI autocontouring. The software works well, saves significant amounts of time and will be efficient to deploy throughout Brazil to start helping clinics save time immediately.” Aguinaldo Leme, CEO - Medintec Latin America.
About Limbus AI Inc.
At Limbus AI Inc., our passionate team of healthcare and technology specialists is dedicated to improving cancer care through the development of state-of-the-art software. Our machine learning-based products improve efficiency and clinical workflows in cancer radiation treatment planning. We specialize in the creation of artificial intelligence (AI)-driven automatic contouring algorithms performed entirely on customers' existing clinical workstations within the security of their own local network. These unique software solutions enable clinicians to plan accurate treatments quicker, with the same resources - allowing centers to meet the ever-growing demand for radiotherapy. Limbus AI is headquartered in Regina Saskatchewan, Canada. To learn more, visit www.limbus.ai or follow us on our social media.
With more than 20 years of experience supplying and manufacturing radiotherapy equipment and services, Medintec Latin America was created to offer technological innovation options in the medical field. It was the first company in Brazil to start manufacturing accessories using thermoplastic materials for the immobilization and positioning of patients undergoing Radiotherapy. We operate in the largest hospitals in Brazil and we are a company that invests in research and development. We always seek to improve our products and services to ensure better treatment for patients. We respect all the standards of the RDC-16, referring to ANVISA's Good Manufacturing Practices for Medical Products. Our mission is to provide products so that patients can have a more reliable and quality treatment. The company's values are based on ethics, professional execution of services, commitment to the client and constant search for innovation and quality. To learn more, visit www.medintec.com.br/home/.
Sept 21, 2022
Limbus AI Appoints Dr. Karl Otto as CEO
REGINA, Saskatchewan, Canada Sept 21, 2022 - Limbus AI Inc. announces the appointment of Dr. Karl Otto to the role of Chief Executive Officer (CEO).
“Limbus AI is growing rapidly. The success of our flagship AI autocontouring product, Limbus Contour, has provided us with the confidence and resources to develop other novel technologies that also help cancer patients” explains Dr. Otto. “Limbus AI has an excellent team that has proven its ability to build and deploy a great product. Working closely with the other founders, I will use my expertise and experience to guide the company through the next phase of growth and build on our successes.”
Co-founder and Medical Director Dr. Joshua Giambattista had previously been serving as the acting CEO of the company since its inception.
Dr. Otto - “We are very fortunate to have Dr. Giambattista’s continued leadership in developing clinician focused products. Limbus Contour is well known for its superior accuracy and clinical utility - a direct result of Dr. Giambattista’s work.”
Dr. Karl Otto has a PhD in Medical Physics with over 25 years of clinical, academic and commercial experience improving the field of radiation therapy. Dr. Otto has received awards for several important scientific publications and innovations, including his invention of VMAT (Volumetric Modulated Arc Therapy) which was licensed to Varian Medical Systems and marketed as RapidArc. VMAT is now the most common form of radiation treatment used globally. Dr. Otto also founded the company HyperDrive Medical which was subsequently acquired by Varian Medical Systems in 2015. Since joining Limbus AI in 2018, he has had an active role in several key areas of the company, including innovation and business development.
June 2, 2022
Accuray and Limbus AI Inc. Partner to Leverage Limbus' Innovative AI-driven Technology to Enhance Accuray Adaptive Radiotherapy Solutions
Partnership will Enable Accuray to Use Limbus' Technology to Streamline the Treatment Planning Process and Increase Operational Efficiency
SUNNYVALE, Calif. and SASKATCHEWAN, Canada, June 2, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and Limbus AI Inc. announced today they are partnering to augment Accuray adaptive radiotherapy capabilities by leveraging Limbus' artificial intelligence (AI)-driven autocontouring algorithms - enabling automated contouring to further streamline the treatment planning process*. The companies expect an integrated offering to be made available beginning in 2023.
Changes in tumor size, shape and location, or in the position of organs and other healthy tissue due to weight gain or loss during the course of radiation therapy, may require adaptation of the treatment plan to ensure the radiation dose remains targeted on the tumor while avoiding nearby sensitive organs. Modifications to plans as part of the adaptive workflow, however, can be prohibitively time consuming and labor intensive. Contouring – defining the border of the tumor and organs at risk – is one of the most critical steps in the planning process and accounts for a significant proportion of both the personnel and time involved in plan adaptation.
"We're thrilled to be working closely with the Accuray team to bring our AI models directly to the treatment machine, where accuracy and efficiency are critical to providing the best patient care. Both companies are focused on providing the best tools to clinicians to enhance radiotherapy treatment delivery," said Dr. Joshua Giambattista, CEO and Medical Director of Limbus AI. "We are confident that our AI models will continue to set the standard for automatic contouring for all treatment plans, including those used in adaptive therapy. This technology will improve efficiency for clinicians, enabling optimal treatment planning in a shorter period of time. These advances will expand utilization of treatment machines so more patients can receive state of the art care."
*Works in progress.
January 31, 2022
Icon Oncology and Limbus AI™ partner to pioneer radiation AI software in SA.
A first implementation of time-saving software to benefit local cancer patients
Leading value-based care (VBC) business, Icon Oncology today announced a partnership with Limbus AI™. The agreement will introduce cutting-edge artificial intelligence (AI) powered software designed to use in radiation oncology to Southern Africa.
“We are proud to announce the implementation of Limbus Contour™ software across our national network of radiation oncology facilities. Icon Oncology has always been at the forefront of using new generation technology and software. We believe Limbus AI™ supports our strategy of using technology to deliver the best possible outcomes for our patients,” says Dr Ernst Marais, COO of Icon Oncology.
“At Limbus AI, our goal is design tools that work. Using our own clinical experience as a guide, we’ve engineered Limbus Contour to save time and improve quality by allowing clinicians to focus on patient care. We believe our partnership with Icon Oncology will help to create much needed capacity in the Southern African region to address the increasing demand for access to cancer care,” says Dr Joshua Giambattista, founder and medical director of Limbus AI.
The software is designed to reduce the planning time it takes before a patient can start radiation therapy, explains Ivan Oelofse, National Medical Physics Manager for Icon Oncology...
June 15, 2021
Limbus AI Receives CE Mark Certification for Limbus Contour
Saskatchewan, Canada. June 7th, 2021 - Limbus AI announces CE mark certification for Limbus Contour, the company’s artificial intelligence (AI) automatic segmentation software. Limbus AI specializes in effective, fully automated radiation oncology contouring solutions backed by clinically validated research and real-world results. In partnership with an established network of international clinics and research partners, the company has proven the accuracy of Limbus Contour with extensive clinical implementation and comprehensive peer-reviewed publications.
“Cancer treatments have become more complex and the number of patients treated continues to grow each year. Limbus Contour adds capacity to meet this growing demand. The software is simple, effective and allows clinicians to focus on complex planning tasks and patient care.” - Karl Otto, Director of Limbus AI
Limbus Contour has established a reputation for high quality and reliable AI automatic contouring, performed on existing workstations with no cloud transfer of patient data required. The software has already reduced planning times for thousands of radiation therapy patients in North America. With CE Mark certification, Limbus AI is now poised to bring its proven automatic contouring solution to the European market. The company will continue its mission to provide the highest quality and most reliable automatic contours on the market, while growing the offering to multimodality AI automatic contouring.
June 15, 2021
Limbus AI Partners with AMG Medtech UK
Limbus AI announces partnership with AMG Medtech Ltd for exclusive distribution of Limbus Contour, a revolutionary artificial intelligence (AI) powered automatic contouring software for radiation oncology. Together, both companies aim to improve cancer care across the UK, Ireland and Benelux, by providing an AI automatic contouring solution that has been proven to increase productivity and decrease the time required for planning critical radiation therapy treatments.
“AMG Medtech Ltd fully understand the importance of an accurate AI autocontouring system and that’s why we are delighted to be partnering with Limbus AI.
The new CE Mark for Limbus Contour finally brings the most advanced AI system into the UK, Ireland and European markets that ensures total patient data security.
Across Europe, the COVID-19 pandemic has accelerated the implementation of new treatment protocols, such as SABR in the UK. These changes reduce the number of required hospital visits for patients, but increases the demand for resources to plan the treatments. Limbus Contour can help to facilitate this change by automating a significant portion of the added workload
Created and supported by a team of physicists and oncologists with a history of bringing ground-breaking RT technology to market, the vendor neutral Limbus Contour has the unique ability to be installed in minutes onto existing computers, ensuring all patient data stays local and secure with no cloud transfer required. Limbus Contour works fast and produces automatically generated, high quality contours.” - AMG Medtech Ltd.
About AMG Medtech
AMG Medtech is a specialist consultancy service and offers distribution of medical AI technologies across the UK, Ireland and Europe. Our team brings over 18 years of experience and expertise in medical imaging, cardiology and radiotherapy. We understand workflows and how to scale them for different departments and across geographical networks, so that you can deliver quality treatment with efficiency and consistency.
AMG Medtech understands the challenges hospitals and cancer clinics face every day with limited resources, such as a lack of trained staff and overwhelming clinician workloads. This inadvertently takes a toll on patient care and treatment. We are excited to bring the advantages of AI into healthcare to reduce the number of routine tasks for clinicians and to raise the standard of care.
June 15, 2021
Limbus AI Partners With France Based Distributor: Irudigi
Limbus AI has partnered with Irudigi to bring Limbus Contour, its flagship product, to Germany, France, Austria and Switzerland.
Irudigi is a medical imaging technology distributor based in France with over 10 years of experience. Through this new partnership, Irudigi will help bring Limbus Contour to market via an extensive network of hospitals and clinics. The company focuses on innovative deep learning and AI solutions applied to medical imaging and oncology. Irudigi’s extensive network, total commitment to hands-on customer service and track record of end-user satisfaction make it a perfect match for Limbus AI solutions and will be the key drivers to the successful commercial launch of Limbus Contour in Europe.
June 15, 2021
Limbus AI Announces Italian Distribution Partnership with DosimETrICA
For more than 10 years, Dosimetrica has supplied advanced dosimetry tools and consulting services for radiotherapy. The company’s mission is to facilitate the most appropriate therapy and safest treatment for cancer patients through the distribution of cutting-edge medical technology.
November 3, 2020
Battling Cancer with Artificial Intelligence
Limbus AI discusses automatic contouring in radiation therapy and company background with ThinkSask.
October 14, 2020
Researchers from Limbus AI and BC Cancer Recieve ASM Award at CARO 2020
Abstract published by researchers from BC Cancer Agency and Limbus AI recieves ASM Award for Best Abstract in Science and Technology at CARO 2020.
Implementation of Deep Learning-Based Auto-Segmentation for Radiotherapy Planning Structures: A Multi-Center Workflow Study.
September 18, 2020
Limbus AI receives FDA clearance for Limbus Contour
Limbus AI announces 510(k) clearance from the U.S. Food and Drug Administration for Limbus Contour, the company’s artificial intelligence (AI) powered automatic contouring software. Limbus AI is focused on the development of products designed to improve efficiency in cancer diagnosis, treatment, and follow up. Their flagship product, Limbus Contour, is backed by comprehensive research and produces clinical grade contours that are revolutionizing the speed of planning radiation therapy treatments.
“With Limbus Contour, clinicians have significantly reduced contouring time, allowing them to dedicate more time to direct patient care.
We believe our product will set the standard for AI based automatic contouring and dramatically improve the productivity in any radiotherapy department. The product shows expert level performance, is simple to use and integrates with any treatment planning platform.” - Dr. Joshua Giambattista, Medical Lead, Limbus AI.
510(k) clearance for Contour is a significant milestone for Limbus AI. The company will now be seeking to expand into the US market while continuing the development of additional AI contouring products. With an established network of international clinical partners and a growing list of peer reviewed research publications, Limbus AI is well positioned to develop, validate and market test new AI based products for cancer care.
June 28, 2019
Limbus AI discusses automatic contouring with ProKnow Systems
In this episode of The Fraction, Ben talks to three of the founders of Limbus AI, a Canadian startup company specializing in machine learning automation to produce anatomy contours.
This episode includes live demonstrations of their software in action, where we use the ProKnow Contouring Accuracy Program to compare their automated contours to physician experts as well as to populations of radiation therapy professionals.